indomethacin has been researched along with Blindness in 5 studies
Indomethacin: A non-steroidal anti-inflammatory agent (NSAID) that inhibits CYCLOOXYGENASE, which is necessary for the formation of PROSTAGLANDINS and other AUTACOIDS. It also inhibits the motility of POLYMORPHONUCLEAR LEUKOCYTES.
indometacin : A member of the class of indole-3-acetic acids that is indole-3-acetic acid in which the indole ring is substituted at positions 1, 2 and 5 by p-chlorobenzoyl, methyl, and methoxy groups, respectively. A non-steroidal anti-inflammatory drug, it is used in the treatment of musculoskeletal and joint disorders including osteoarthritis, rheumatoid arthritis, gout, bursitis and tendinitis.
Blindness: The inability to see or the loss or absence of perception of visual stimuli. This condition may be the result of EYE DISEASES; OPTIC NERVE DISEASES; OPTIC CHIASM diseases; or BRAIN DISEASES affecting the VISUAL PATHWAYS or OCCIPITAL LOBE.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The prophylactic administration of indomethacin reduces the frequency of patent ductus arteriosus and severe intraventricular hemorrhage in very-low-birth-weight infants (those with birth weights below 1500 g)." | 5.09 | Long-term effects of indomethacin prophylaxis in extremely-low-birth-weight infants. ( Davis, P; Moddemann, D; Ohlsson, A; Roberts, RS; Saigal, S; Schmidt, B; Solimano, A; Vincer, M; Wright, LL, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (20.00) | 18.2507 |
| 2000's | 3 (60.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wickremasinghe, AC | 1 |
| Rogers, EE | 1 |
| Piecuch, RE | 1 |
| Johnson, BC | 1 |
| Golden, S | 1 |
| Moon-Grady, AJ | 1 |
| Clyman, RI | 1 |
| Schmidt, B | 2 |
| Asztalos, EV | 1 |
| Roberts, RS | 2 |
| Robertson, CM | 1 |
| Sauve, RS | 1 |
| Whitfield, MF | 1 |
| Toler, SM | 1 |
| Gandolfi, SA | 1 |
| Vecchi, M | 1 |
| Braccio, L | 1 |
| Davis, P | 1 |
| Moddemann, D | 1 |
| Ohlsson, A | 1 |
| Saigal, S | 1 |
| Solimano, A | 1 |
| Vincer, M | 1 |
| Wright, LL | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Trial of Indomethacin Prophylaxis in Preterm Infants (TIPP)[NCT00009646] | Phase 3 | 1,202 participants (Actual) | Interventional | 1993-11-30 | Completed | ||
| Lactoferrin Infant Feeding Trial - LIFT_Canada[NCT03367013] | Phase 3 | 453 participants (Actual) | Interventional | 2018-02-16 | Active, not recruiting | ||
| Enteral Supplementation With High-dose Docosahexaenoic Acid on the Risk for Bronchopulmonary Dysplasia in Very Preterm Infants: A Collaborative Study Protocol for an Individual Participant Data Meta-analysis[NCT05915806] | 1,801 participants (Actual) | Interventional | 2023-07-30 | Active, not recruiting | |||
| Clinical Research on the Predictive Effect of Neonatal Morbidities on the Poor Outcomes to Very Low Birth-weight and Extremely Low Birth-weight Infants[NCT03104946] | 834 participants (Actual) | Observational | 2013-09-01 | Completed | |||
| High-Dose Erythropoietin in Very Low Birth Weight Infants for the Potential Treatment of Prematurity-Related Cerebral Hemorrhagic-Ischemic Injury: A Phase II Safety/Tolerability Study[NCT00589953] | Phase 2 | 22 participants (Actual) | Interventional | 2007-07-31 | Terminated | ||
| Follow-up Visit of High Risk Infants[NCT00009633] | 68,000 participants (Anticipated) | Observational | 1993-01-31 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for indomethacin and Blindness
| Article | Year |
|---|---|
Oxidative stress plays an important role in the pathogenesis of drug-induced retinopathy.
Topics: Animals; Blindness; Chloroquine; Humans; Indomethacin; Oxidative Stress; Retina; Retinal Diseases; T | 2004 |
3 trials available for indomethacin and Blindness
| Article | Year |
|---|---|
Impact of bronchopulmonary dysplasia, brain injury, and severe retinopathy on the outcome of extremely low-birth-weight infants at 18 months: results from the trial of indomethacin prophylaxis in preterms.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blindness; Brain Diseases; Bronchopulmonary Dysplasia; Cere | 2003 |
Impact of bronchopulmonary dysplasia, brain injury, and severe retinopathy on the outcome of extremely low-birth-weight infants at 18 months: results from the trial of indomethacin prophylaxis in preterms.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blindness; Brain Diseases; Bronchopulmonary Dysplasia; Cere | 2003 |
Impact of bronchopulmonary dysplasia, brain injury, and severe retinopathy on the outcome of extremely low-birth-weight infants at 18 months: results from the trial of indomethacin prophylaxis in preterms.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blindness; Brain Diseases; Bronchopulmonary Dysplasia; Cere | 2003 |
Impact of bronchopulmonary dysplasia, brain injury, and severe retinopathy on the outcome of extremely low-birth-weight infants at 18 months: results from the trial of indomethacin prophylaxis in preterms.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blindness; Brain Diseases; Bronchopulmonary Dysplasia; Cere | 2003 |
Impact of bronchopulmonary dysplasia, brain injury, and severe retinopathy on the outcome of extremely low-birth-weight infants at 18 months: results from the trial of indomethacin prophylaxis in preterms.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blindness; Brain Diseases; Bronchopulmonary Dysplasia; Cere | 2003 |
Impact of bronchopulmonary dysplasia, brain injury, and severe retinopathy on the outcome of extremely low-birth-weight infants at 18 months: results from the trial of indomethacin prophylaxis in preterms.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blindness; Brain Diseases; Bronchopulmonary Dysplasia; Cere | 2003 |
Impact of bronchopulmonary dysplasia, brain injury, and severe retinopathy on the outcome of extremely low-birth-weight infants at 18 months: results from the trial of indomethacin prophylaxis in preterms.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blindness; Brain Diseases; Bronchopulmonary Dysplasia; Cere | 2003 |
Impact of bronchopulmonary dysplasia, brain injury, and severe retinopathy on the outcome of extremely low-birth-weight infants at 18 months: results from the trial of indomethacin prophylaxis in preterms.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blindness; Brain Diseases; Bronchopulmonary Dysplasia; Cere | 2003 |
Impact of bronchopulmonary dysplasia, brain injury, and severe retinopathy on the outcome of extremely low-birth-weight infants at 18 months: results from the trial of indomethacin prophylaxis in preterms.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blindness; Brain Diseases; Bronchopulmonary Dysplasia; Cere | 2003 |
Impact of bronchopulmonary dysplasia, brain injury, and severe retinopathy on the outcome of extremely low-birth-weight infants at 18 months: results from the trial of indomethacin prophylaxis in preterms.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blindness; Brain Diseases; Bronchopulmonary Dysplasia; Cere | 2003 |
Impact of bronchopulmonary dysplasia, brain injury, and severe retinopathy on the outcome of extremely low-birth-weight infants at 18 months: results from the trial of indomethacin prophylaxis in preterms.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blindness; Brain Diseases; Bronchopulmonary Dysplasia; Cere | 2003 |
Impact of bronchopulmonary dysplasia, brain injury, and severe retinopathy on the outcome of extremely low-birth-weight infants at 18 months: results from the trial of indomethacin prophylaxis in preterms.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blindness; Brain Diseases; Bronchopulmonary Dysplasia; Cere | 2003 |
Impact of bronchopulmonary dysplasia, brain injury, and severe retinopathy on the outcome of extremely low-birth-weight infants at 18 months: results from the trial of indomethacin prophylaxis in preterms.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blindness; Brain Diseases; Bronchopulmonary Dysplasia; Cere | 2003 |
Impact of bronchopulmonary dysplasia, brain injury, and severe retinopathy on the outcome of extremely low-birth-weight infants at 18 months: results from the trial of indomethacin prophylaxis in preterms.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blindness; Brain Diseases; Bronchopulmonary Dysplasia; Cere | 2003 |
Impact of bronchopulmonary dysplasia, brain injury, and severe retinopathy on the outcome of extremely low-birth-weight infants at 18 months: results from the trial of indomethacin prophylaxis in preterms.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blindness; Brain Diseases; Bronchopulmonary Dysplasia; Cere | 2003 |
Impact of bronchopulmonary dysplasia, brain injury, and severe retinopathy on the outcome of extremely low-birth-weight infants at 18 months: results from the trial of indomethacin prophylaxis in preterms.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blindness; Brain Diseases; Bronchopulmonary Dysplasia; Cere | 2003 |
Decrease of intraocular pressure after subconjunctival injection of mitomycin in human glaucoma.
Topics: Adult; Aged; Aqueous Humor; Blindness; Conjunctiva; Female; Glaucoma; Humans; Indomethacin; Injectio | 1995 |
Long-term effects of indomethacin prophylaxis in extremely-low-birth-weight infants.
Topics: Blindness; Cerebral Palsy; Cognition Disorders; Ductus Arteriosus, Patent; Enterocolitis, Necrotizin | 2001 |
Long-term effects of indomethacin prophylaxis in extremely-low-birth-weight infants.
Topics: Blindness; Cerebral Palsy; Cognition Disorders; Ductus Arteriosus, Patent; Enterocolitis, Necrotizin | 2001 |
Long-term effects of indomethacin prophylaxis in extremely-low-birth-weight infants.
Topics: Blindness; Cerebral Palsy; Cognition Disorders; Ductus Arteriosus, Patent; Enterocolitis, Necrotizin | 2001 |
Long-term effects of indomethacin prophylaxis in extremely-low-birth-weight infants.
Topics: Blindness; Cerebral Palsy; Cognition Disorders; Ductus Arteriosus, Patent; Enterocolitis, Necrotizin | 2001 |
Long-term effects of indomethacin prophylaxis in extremely-low-birth-weight infants.
Topics: Blindness; Cerebral Palsy; Cognition Disorders; Ductus Arteriosus, Patent; Enterocolitis, Necrotizin | 2001 |
Long-term effects of indomethacin prophylaxis in extremely-low-birth-weight infants.
Topics: Blindness; Cerebral Palsy; Cognition Disorders; Ductus Arteriosus, Patent; Enterocolitis, Necrotizin | 2001 |
Long-term effects of indomethacin prophylaxis in extremely-low-birth-weight infants.
Topics: Blindness; Cerebral Palsy; Cognition Disorders; Ductus Arteriosus, Patent; Enterocolitis, Necrotizin | 2001 |
Long-term effects of indomethacin prophylaxis in extremely-low-birth-weight infants.
Topics: Blindness; Cerebral Palsy; Cognition Disorders; Ductus Arteriosus, Patent; Enterocolitis, Necrotizin | 2001 |
Long-term effects of indomethacin prophylaxis in extremely-low-birth-weight infants.
Topics: Blindness; Cerebral Palsy; Cognition Disorders; Ductus Arteriosus, Patent; Enterocolitis, Necrotizin | 2001 |
1 other study available for indomethacin and Blindness
| Article | Year |
|---|---|
Neurodevelopmental outcomes following two different treatment approaches (early ligation and selective ligation) for patent ductus arteriosus.
Topics: Age Factors; Blindness; Cardiovascular Agents; Cerebral Palsy; Child, Preschool; Combined Modality T | 2012 |